ZOE Stock Overview
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$154.46 |
| 52 Week High | US$159.20 |
| 52 Week Low | US$154.46 |
| Beta | 0.76 |
| 1 Month Change | 0% |
| 3 Month Change | 0.97% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZOE | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | 0.2% |
| 1Y | n/a | 5.9% | 15.7% |
Return vs Industry: Insufficient data to determine how ZOE performed against the BG Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ZOE performed against the BG Market.
Price Volatility
| ZOE volatility | |
|---|---|
| ZOE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in BG Market | 7.0% |
| 10% least volatile stocks in BG Market | 2.2% |
Stable Share Price: ZOE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ZOE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 13,800 | Kristin Peck | www.zoetis.com |
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives.
Zoetis Inc. Fundamentals Summary
| ZOE fundamental statistics | |
|---|---|
| Market cap | €74.34b |
| Earnings (TTM) | €1.92b |
| Revenue (TTM) | €7.34b |
38.7x
P/E Ratio10.1x
P/S RatioIs ZOE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZOE income statement (TTM) | |
|---|---|
| Revenue | US$8.08b |
| Cost of Revenue | US$2.45b |
| Gross Profit | US$5.63b |
| Other Expenses | US$3.52b |
| Earnings | US$2.11b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 04, 2023
| Earnings per share (EPS) | 4.57 |
| Gross Margin | 69.73% |
| Net Profit Margin | 26.16% |
| Debt/Equity Ratio | 180.3% |
How did ZOE perform over the long term?
See historical performance and comparison